Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction

Open Heart

Volumn 1, Issue 1, 2014, Pages

  Andell, Pontus ^a   Koul, Sasha ^a   Martinsson, Andreas ^a   Sundström, Johan ^b   Jernberg, Tomas ^c   Smith, J Gustav ^a   James, Stefan ^b   Lindahl, Bertil ^b   Erlinge, David ^a  

^a LUND UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENTING; DISEASE ASSOCIATION; DUAL ANTIPLATELET THERAPY; DYSPNEA; FEMALE; HEART ATRIUM FLUTTER; HEART FAILURE; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEART REINFARCTION; HEART RIGHT BUNDLE BRANCH BLOCK; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NEW ONSET BLEEDING; NEW ONSET HEART FAILURE; NEW ONSET STROKE; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSITIVE END EXPIRATORY PRESSURE; PROGNOSTIC ASSESSMENT; PROTEIN BLOOD LEVEL; QRS COMPLEX; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORAX PAIN;

EID: 84984596891     PISSN: None     EISSN: 20533624     Source Type: Journal    
DOI: 10.1136/openhrt-2013-000002     Document Type: Article

References (38)

1. WHO. World Health Statistics. 2008. http://www.who.int/whosis/whostat/EN-WHS08-Full.pdf
2. Mackay J, Eriksen M. WHO atlas maps global tobacco epidemic. Public Health Rep 2002;117:479.
3. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006;28:523-32.
4. Lindstrom M, Jonsson E, Larsson K, et al. Underdiagnosis of chronic obstructive pulmonary disease in Northern Sweden. Int J Tuberc Lung Dis 2002;6:76-84.
5. Pena VS, Miravitlles M, Gabriel R, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 2000;118:981-9.
6. Make B, Dutro MP, Paulose-Ram R, et al. Undertreatment of COPD: a retrospective analysis of US managed care and medicare patients. Int J Chron Obstruct Pulmon Dis 2012;7:1-9.
7. Bednarek M, Maciejewski J, Wozniak M, et al. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax 2008;63:402-7.
8. Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994;309:901-11.
9. Rabe KF. Treating COPD - the TORCH trial, P values, and the Dodo. N Engl J Med 2007;356:851-4.
10. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497-505.
11. Lofdahl CG. COPD and co-morbidities, with special emphasis on cardiovascular conditions. Clin Respir J 2008;2(Suppl 1):59-63.
12. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
13. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005;127:1952-9.
14. Engstrom G, Wollmer P, Hedblad B, et al. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from 'men born in 1914,' Malmo, Sweden. Circulation 2001;103:3086-91.
15. Mannino DM, Watt G, Hole D, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006;27:627-43.
16. Hole DJ, Watt GC, Davey-Smith G, et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996;313:711-15; discussion 5-6.
17. Calverley PM, Scott S. Is airway inflammation in chronic obstructive pulmonary disease (COPD) a risk factor for cardiovascular events? COPD 2006;3:233-42.
18. Engstrom G, Lindberg C, Gerhardsson de Verdier M, et al. Blood biomarkers and measures of pulmonary function - a study from the Swedish twin registry. Respir Med 2012;106:1250-7.
19. McAllister DA, Maclay JD, Mills NL, et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:1208-14.
20. Hadi HA, Zubaid M, Al Mahmeed W, et al. Prevalence and prognosis of chronic obstructive pulmonary disease among 8167 Middle Eastern patients with acute coronary syndrome. Clin Cardiol 2010;33:228-35.
21. Bursi F, Vassallo R, Weston SA, et al. Chronic obstructive pulmonary disease after myocardial infarction in the community. Am Heart J 2010;160:95-101.
22. Salisbury AC, Reid KJ, Spertus JA. Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes. Am J Cardiol 2007;99:636-41.
23. Jernberg T, Attebring MF, Hambraeus K, et al. The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Heart 2010;96:1617-21.
24. Swedish National Board of Health and Welfare. Swedish National Patient Register. http://www.socialstyrelsen.se/register/halsodataregister/patientregistret/inenglish
25. Inghammar M, Engstrom G, Lofdahl CG, et al. Validation of a COPD diagnosis from the Swedish Inpatient Registry. Scand J Public Health 2012;40:773-6.
26. Textor J, Hardt J, Knuppel S. DAGitty: a graphical tool for analyzing causal diagrams. Epidemiology 2011;22:745.
27. Wakabayashi K, Gonzalez MA, Delhaye C, et al. Impact of chronic obstructive pulmonary disease on acute-phase outcome of myocardial infarction. Am J Cardiol 2010;106:305-9.
28. Egred M, Shaw S, Mohammad B, et al. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM 2005;98:493-7.
29. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;(4):CD003566.
30. Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47:2554-60.
31. Janda S, Park K, FitzGerald JM, et al. Statins in COPD: a systematic review. Chest 2009;136:734-43.
32. Behar S, Panosh A, Reicher-Reiss H, et al. Prevalence and prognosis of chronic obstructive pulmonary disease among 5,839 consecutive patients with acute myocardial infarction. SPRINT Study Group. Am J Med 1992;93:637-41.
33. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165-85.
34. Rutten FH, Cramer MJ, Lammers JW, et al. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail 2006;8:706-11.
35. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003;21:892-905.
36. Vizza CD, Lynch JP, Ochoa LL, et al. Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest 1998;113:576-83.
37. Damarla M, Celli BR, Mullerova HX, et al. Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respir Care 2006;51:1120-4.
38. Ingelsson E, Arnlov J, Sundstrom J, et al. The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail 2005;7:787-91.